Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2016-07-07 Legal Proceedings Report
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 1% confidence The document is a press release dated July 7, 2016, announcing a new collaboration between Onxeo and the Royal College of Surgeons in Ireland regarding research on Beleodaq® derivatives. It details the scope of the research, terms of the agreement, and provides updates on the company's pipeline and general corporate information. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial event report (like DIV or CAP), falls best under the general category of corporate news or regulatory announcements that don't fit elsewhere. Since it is a specific corporate update that is not a formal financial report or a specific insider/shareholder event, and it is not explicitly announcing the publication of a major report (RPA), the most appropriate general category is Regulatory Filings (RNS) as a catch-all for press releases detailing business developments.
2016-07-07 English
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release dated July 4, 2016, announcing that Onxeo received a 'Notice of Allowance' from the USPTO for a key patent related to its AsiDNA product. The content focuses entirely on intellectual property (IP) protection, patent terms, and the strategic value of this IP. This type of announcement, detailing specific legal/IP developments rather than financial results (ER/IR) or management changes (MANG), fits best under a category related to corporate actions or regulatory updates. Since it is a specific announcement about intellectual property rights and patent status, it is most closely related to Investor Presentation (IP) or Regulatory Filings (RNS). However, given the focus on patent protection, which is a core component of investor value and often disclosed via press release, and the lack of a specific 'IP Filing' category, 'Regulatory Filings' (RNS) serves as the most appropriate general category for specific, non-financial, non-governance regulatory/legal updates that aren't LTR (Legal Proceedings Report). It is not an ER, IR, or a formal legal proceeding report (LTR). It is a specific announcement about IP protection, which falls under general regulatory/corporate news.
2016-07-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo, dated July 4, 2016, announcing the receipt of a patent grant from the US Patent Office concerning its drug candidate AsiDNA™. The content focuses on intellectual property protection, patent details, and strategic implications for the company's pipeline. This type of announcement, detailing specific corporate developments (like patent grants, clinical trial updates, or financing news) released via press release, typically falls under a general regulatory announcement or a specific category if one fits better. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A), and it is not explicitly announcing the publication of a report (RPA), the most appropriate general category for a significant, non-financial corporate event announcement is Regulatory Filings (RNS). While it relates to intellectual property, there is no specific 'IP' or 'Legal' category that perfectly captures a patent grant announcement, making RNS the best fit as a general regulatory/corporate update.
2016-07-04 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release from Onxeo dated June 27, 2016, announcing its development plan for the drug candidate AsiDNA. It details preclinical and clinical milestones, manufacturing optimization, and provides an outlook. This type of announcement, detailing strategic plans, pipeline updates, and future expected results, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing strategy and future milestones rather than a full financial report (10-K, IR) or a simple earnings highlight (ER), 'Investor Presentation' (IP) is the most fitting category for strategic corporate communication aimed at investors, even though it is presented as a press release. It is not a short announcement linking to a separate report, so RPA/RNS is less appropriate than IP.
2016-06-27 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is a press release dated June 27, 2016, announcing an update to the development plan for the compound AsiDNA, including near-term milestones and expected newsflow (preclinical results, manufacturing optimization, and clinical trial launch). It discusses strategy, preclinical/clinical data summaries, and future outlook. This type of announcement, detailing operational and strategic updates outside of mandatory periodic financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses heavily on pipeline advancement and future milestones rather than just summarizing period-end financial results (which would be ER), and it is not a transcript (CT), investor presentation (IP), or a formal regulatory filing announcement (RPA/RNS), it best fits the 'Earnings Release' category as it serves as the primary communication of recent operational progress to the market, often released concurrently with or instead of a full earnings report. Given the focus on development plans and milestones, it aligns closely with the intent of an ER, even if it's not strictly Q/Y results. Q4 2016
2016-06-27 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated June 2, 2016, announcing positive preliminary results from a preclinical pharmacokinetic study for a new oral formulation of their drug Beleodaq®. It details scientific progress, next steps (selecting a formulation technology, refining dosage, starting clinical development), and includes commentary from management. This type of announcement, focusing on operational and scientific development milestones rather than comprehensive periodic financial results (like 10-K or IR), capital structure changes (CAP), or management changes (MANG), fits best under a general announcement category. Since it is an announcement of scientific progress and development updates, it is not a formal regulatory filing like 10-K or IR. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Investor Presentation (IP). Given the content is a specific corporate update about drug development progress, it is most closely aligned with a general corporate announcement. Since there isn't a specific 'R&D Update' category, and it's not a formal financial report, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general corporate announcement, although it functions similarly to an Investor Presentation update, it lacks the typical structure of a formal IP. However, upon re-evaluation, this is a specific corporate development announcement detailing scientific progress, which often falls under general news releases. Given the options, and noting it is a detailed update on a specific product's development path, it is a significant corporate communication. It is not a formal financial report (10-K, IR, ER, MRQ). It is not a proxy/governance document. It is a specific operational update. In the absence of a dedicated 'R&D Update' or 'Press Release' category, 'RNS' (Regulatory Filings/General Announcements) is the standard fallback for non-standard, material corporate news releases.
2016-06-02 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.